04:38 PM EDT, 09/18/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) on late Wednesday unveiled an underwritten public offering of $300 million of American depositary shares, subject to market and other conditions.

Each ADS to be offered represents one ordinary share of the company, it said.

Ascendis said it expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of ADSs at the public offering price.

There is no assurance on the completion and the actual size or terms of the offering, the company added.

Shares of the company were down 4.3% in recent after-hours activity.

Price: 142.50, Change: -6.38, Percent Change: -4.29